This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →
EAN 2026: following EU approval, AbbVie highlights Aquipta efficacy for acute migraine
AbbVie presented new results from the Phase III ECLIPSE trial (NCT06241313) at this year's Congress of the European Academy of Neurology (EAN).
By Pharmaceutical Technology
· Jul 1, 2026
· via Pharmaceutical Technology
Image: Pharmaceutical Technology
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Tara Sparks was just days away from starting her new job at Novo Nordisk in February 2025 when she gathered wi…
The WeekFierceBiotech ↗
QuantumCell has licensed AlzeCure Pharma's Alzheimer's disease platform and lead asset for $12 million upfront…
The WeekBriefing
FDA approved Orca Bio’s Tregzi, the first allogeneic regulatory T cell therapy for blood cancer patients needi…